In Reply Pang et al raised the concern of immune thrombocytopenia being neglected as an adverse event associated with programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors in clinical trials. This perceived oversight may have stemmed from the low incidence of thrombocytopenia reported in clinical trials of PD-1 and PD-L1 inhibitors, the challenge in diagnosing immune thrombocytopenia, and the potential life-threatening severity of immune thrombocytopenia in rare cases.